base-excision restriction enzyme in stomach carcinogenesis.
1/5 보강
Many recent lines of evidence from the human microbiome and other fields indicate bacterial involvement in various types of cancer.
APA
Fukuyo M, Takahashi N, et al. (2025). base-excision restriction enzyme in stomach carcinogenesis.. PNAS nexus, 4(8), pgaf244. https://doi.org/10.1093/pnasnexus/pgaf244
MLA
Fukuyo M, et al.. " base-excision restriction enzyme in stomach carcinogenesis.." PNAS nexus, vol. 4, no. 8, 2025, pp. pgaf244.
PMID
40842971 ↗
Abstract 한글 요약
Many recent lines of evidence from the human microbiome and other fields indicate bacterial involvement in various types of cancer. has been recognized as the major cause of stomach cancer (gastric cancer), but the mechanism by which it destabilizes the human genome to cause cancer remains unclear. Our recent studies have identified a unique family of toxic restriction enzymes that excise a base (: adenine) from their recognition sequence (5'-GTC). At the resulting abasic sites (5'-GTC), its inherent endonuclease activity or that of a separate endonuclease may yield atypical strand breaks that resist repair by ligation. Here, we present evidence demonstrating involvement of its member, PabI, in stomach carcinogenesis: (i) Association of intact PabI gene with gastric cancer in the global Genome Project and the open genomes; (ii) Frequent mutations at in 5'-GTC in the gastric cancer genomes as well as in genomes; (iii) Its induction of chromosomal double-strand breaks in infected human cells and of mutagenesis in bacterial test systems. In addition, its unique regions that interact with DNA exhibit signs of diversifying selection. Our further analysis revealed similar oncogenic bacterium-restriction-enzyme pairs for other types of cancer. These results set another stage for cancer research and medicine around oncogenic restriction enzymes.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- Advances in Targeted Therapy for Human Epidermal Growth Factor Receptor 2-Low Tumors: From Trastuzumab to Antibody-Drug Conjugates.
- Blocking SHP2 benefits FGFR2 inhibitor and overcomes its resistance in -amplified gastric cancer.
- Association of preoperative frailty and prognostic nutritional index with postoperative delirium in elderly gastric cancer patients: A single-center observational study.
- Complete response to Nivolumab-based chemotherapy in a case of advanced gastric cancer with multiple immune-related adverse events.
- Apatinib and silver nanoparticles synergize against gastric cancer through the PI3K/Akt signaling pathway-mediated ferroptosis.
- Correction: Survival disparities and predictors in gastric cancer: a population-based study from Kazakhstan (2012-2023).